Keyphrases
Clinical Outcomes
100%
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
100%
MTOR Inhibitor
100%
Pathway Activity
100%
Inhibitor Therapy
100%
FDG Positron Emission Tomography
100%
Tumor
18%
Positron Emission Tomography
18%
Cancer Treatment
18%
Glucose Transporter 1 (GLUT1)
18%
Progressive Disease
18%
AKT1
18%
Akt Activation
18%
European Organizations
18%
Clinical Trials
9%
Clinical Response
9%
Computed Tomography
9%
Plasma Membrane
9%
Positron Emission Tomography-computed Tomography (PET-CT)
9%
18F-fluorodeoxyglucose (18F-FDG)
9%
Proliferative Response
9%
Glycolysis
9%
Rapamycin
9%
Pharmacodynamic Markers
9%
Xenograft Tumor Model
9%
Mammalian Target of Rapamycin Inhibition
9%
Tumor Patients
9%
Metabolic Disease
9%
Objective Response
9%
Response Evaluation Criteria in Solid Tumors (RECIST)
9%
Predictive Marker
9%
Small Animal
9%
Temsirolimus
9%
Advanced Solid Tumors
9%
Anticancer Agents
9%
MTOR Complex 2 (mTORC2)
9%
Murine Xenografts
9%
Quantitative Change
9%
Murine Xenograft Model
9%
Pharmacology, Toxicology and Pharmaceutical Science
Fluorodeoxyglucose F 18
100%
Mammalian Target of Rapamycin Inhibitor
100%
Protein Kinase B
100%
Neoplasm
40%
Malignant Neoplasm
40%
Solid Malignant Neoplasm
40%
Preclinical Study
40%
Glucose Transporter 1
40%
Diseases
40%
Clinical Trial
20%
Pharmacodynamics
20%
Clinical Study
20%
Rapamycin
20%
Mammalian Target of Rapamycin
20%
Temsirolimus
20%
Tumor Model
20%
Mammalian Target of Rapamycin Complex 2
20%
Metabolic Disorder
20%
Anticancer Drug
20%
Medicine and Dentistry
Positron Emission Tomography
100%
Fluorodeoxyglucose F 18
100%
Mammalian Target of Rapamycin Inhibitor
100%
Protein Kinase B
100%
Neoplasm
16%
Cancer Treatment
16%
Xenograft
16%
Progressive Disease
16%
Glucose Transporter 1
16%
Positron Emission Tomography-Computed Tomography
8%
Clinical Trial
8%
Computer Assisted Tomography
8%
Solid Malignant Neoplasm
8%
Cell Membrane
8%
Tumor Model
8%
Pharmacodynamics
8%
Mechanistic Target of Rapamycin
8%
Water-Electrolyte Imbalance
8%
Temsirolimus
8%
Rapamycin
8%
Response Evaluation Criteria in Solid Tumors
8%
Predictive Marker
8%
Mammalian Target of Rapamycin Complex 2
8%
Anticancer Drug
8%
Immunology and Microbiology
Positron Emission Tomography
100%
Sirolimus
100%
Xenograft
16%
Preclinical Study
16%
Positron Emission Tomography-Computed Tomography
8%
Cell Membrane
8%
Computer Assisted Tomography
8%
Pharmacodynamics
8%
Temsirolimus
8%
Mammalian Target of Rapamycin Complex 2
8%